<DOC>
	<DOCNO>NCT01080079</DOCNO>
	<brief_summary>The purpose study determine iontophoretic application terbinafine gel safe effective teh treatment distal subungual onychomycosis</brief_summary>
	<brief_title>Efficacy Safety Study Iontophoretic Application Terbinafine Gel Subjects With Onychomycosis</brief_title>
	<detailed_description />
	<mesh_term>Onychomycosis</mesh_term>
	<mesh_term>Terbinafine</mesh_term>
	<criteria>• Positive clinical finding distal subungual onychomycosis determine clinical examination Must great toenail involvement onychomycosis ≥25≤65 % visible nail . ( one nail maybe affect however index great toenail evaluate ) Nail plate must ≤ 3 mm thick . Must positive KOH positive identification Dermatophyte via culture . Written informed consent must obtain subject . Must ≥ 18 &lt; 70 year age , unless local law dictate otherwise . Must agree avoid type pedicure application nail polish product nail cosmetic toenail screen visit conclusion trial . Must agree take measure avoid pregnancy study period Must agree avoid use oral topical antifungal unless provide investigator relief symptomatic ( active clinical sign ) tinea pedis occur treatment / follow phase study . ( The treatment provide Lotrimin® ) . • The presence proximal subungual onychomycosis white superficial onychomycosis Fungal involvement lunula le 2 mm clear nail proximal nail fold Subjects psoriasis , eczema , symptomatic ( active clinical sign ) interdigital plantar tinea pedis , lichen planus , abnormality ( e.g . traumatize dystrophic nail ) could result clinically abnormal nail investigator think current condition compromise integrity trial Any presence dermatophytoma onychomycotic spike Subjects either uncontrolled diabetes mellitus know diabetic pharmaceutical therapy palpable pedal pulse Subjects peripheral vascular disease Subjects immunosuppressed chronic corticosteroid therapy ( see ) , solid organ bone marrow transplantation , cytotoxic chemotherapy within previous 12 month ( plan within next 12 month ) , HIV infection . Use topical antifungal e.g . ( clotrimazole , ketoconazole , miconazole , oxiconazole ( Oxistat® , Glaxo Smith Kline ) , sulconazole , naftifine ( Naftin® , Merz ) , terconazole , econazole nitrate ( Spectazole® , OrthoMcNeil ) , butoconazole , Fluconazole , tolnaftate , haloprogin ) , ZeasorbAF Ciclopirox ( e.g . Penlac® Nail Lacquer , SanofiAventis ) corticosteroid ( e.g . hydrocortisone , betamethasone , fluticasone mometasone ) precede 15 day Day 1 , immediately around area evaluation . Use systemic corticosteroid within 30 day precede Day 1 Use systemic antifungal precede 120 day Day 1 include ( terbinafine ( Lamisil® , Novartis ) , Itraconazole ( Sporanox® , Janssen ) , fluconazole ( Diflucan® , Pfizer ) , ketoconazole , miconazole , griseofulvin ( GrisPEG® , Pedinol ) , butoconazole , terconazole , potassium iodide , . Has use investigational drug ( ) within 30 day precede Day 1 , exception investigational systemic antifungal ( 120 day ) ) Is pregnant nursing mother Is woman child bear potential use adequate form contraception ( abstinence ) Is &lt; 18 year age , unless local law dictate otherwise . Suffers condition , , opinion medical investigator , would compromise his/her safety / quality data . Subjects pacemaker automatic implantable cardioverter/defibrillator . Subjects implantable electronic device .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Onychomycosis</keyword>
</DOC>